New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rus
- Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy- Rusfertide was associated with lower disease-related symptoms in patients with moderate/severe scores at baseline as assessed by the Myeloproliferati...
United States Dineshv Patel Corey Davis Network Of Companies Exchange Commission Protagonist Therapeutics Inc
Source: pharmiweb.com